For instance, Dyngo has been shown to inhibit Trop2 endocytosis in prostate cancer cells, which can potentially reduce the effectiveness of Trop2-targeting ADCs [76,119]. This evidence concerns the gene TACSTD2 and Familial prostate cancer.